Robin Bone, MD
Obstetrics & Gynecology · New Orleans, LANPI 1972563088
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,420 of the $17,947 with a category attached, or 69.2%. Mayne Pharma Commercial LLC accounts for 82.5% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $14,519, more than ten times the $616 reported in 2019. Among obstetrics & gynecology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $76.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$15K
- AbbVie$714
- Exeltis, USA Inc.$452
- Astellas Pharma US Inc$313
- Sumitomo Pharma America, Inc.$168
- Pfizer$154
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$12,42069%
- Travel & lodging$8545%
- Food & beverage$4,64326%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 69 | $14,800 |
| AbbVie | 36 | $714 |
| Exeltis, USA Inc. | 19 | $452 |
| Astellas Pharma US Inc | 8 | $313 |
| Sumitomo Pharma America, Inc. | 10 | $168 |
| Pfizer | 10 | $154 |
| Amgen | 8 | $141 |
| Biogen | 1 | $125 |
| Myovant Sciences Inc. | 8 | $116 |
| Therapeuticsmd, Inc. | 8 | $97 |
| Evofem Biosciences, Inc. | 13 | $97 |
| Biom'up France SAS | 1 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $72 |
| Mylan Pharmaceuticals Inc. | 5 | $64 |
| Bayer | 4 | $62 |
| Avion Pharmaceuticals | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Millicent US Inc | 3 | $43 |
| Agile Therapeutics, Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $39 |
| Scynexis, Inc. | 2 | $37 |
| Astellas Pharma Global Development | 1 | $36 |
| Merck | 2 | $34 |
| Mission Pharmacal Company | 2 | $32 |
| Coopersurgical, Inc. | 2 | $26 |
| Radius Health, Inc. | 1 | $20 |
| Organon | 1 | $18 |
| Meditrina | 1 | $15 |
| Medtronic | 1 | $14 |
| Lupin Inc. | 1 | $13 |
| BD | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,947 in reported general payments places this provider in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 21 | $14,309 |
| PremarinEstrogens, Conjugated | 21 | $9,002 |
| Estradiol | 191 | $6,962 |
| IntrarosaPrasterone (Dhea) | 25 | $6,605 |
| ImvexxyEstradiol | 15 | $3,188 |
| ProgesteroneProgesterone, Micronized | 80 | $2,254 |
| ValacyclovirValacyclovir Hcl | 19 | $1,435 |
| Clobetasol Propionate | 15 | $584 |
| Solifenacin Succinate | 18 | $439 |
| Ibandronate Sodium | 16 | $350 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $268 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $255 |
| Escitalopram Oxalate | 32 | $200 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $186 |
| Bupropion XlBupropion Hcl | 11 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $313 | $14,30921 claims |
| PfizerPremarin | $154 | $9,00221 claims |
| Therapeuticsmd, Inc.Imvexxy | $97 | $3,18815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.
Other obstetrics & gynecology in New Orleans
- Veronica GillispieNew Orleans$117K
- Earl PeeperNew Orleans$95K
- George MorrisNew Orleans$34K
- Janifer TropezNew Orleans$27K
- Roeland VanopijnenNew Orleans$19K
- Diana DangNew Orleans$17K
- Jennifer BrunetNew Orleans$11K
- Julie TaggartNew Orleans$10K
- Candace MooreNew Orleans$9K
- Andrew JonesNew Orleans$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.